ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
02/09/201610:55:33Amended Statement of Ownership (sc 13g/a)
02/09/201601:00:00Pharming and Cytobioteck Announce Extension of Distribution Agreement...
02/05/201617:06:17Amended Statement of Beneficial Ownership (sc 13d/a)
02/04/201612:57:00Martin Shkreli Takes the Fifth Before Congress--3rd Update
02/04/201611:23:00Martin Shkreli Takes the Fifth Before Congress--2nd Update
02/04/201611:13:00Martin Shkreli Takes the Fifth Before Congress--Update
02/04/201611:00:00Martin Shkreli Takes the Fifth Before Congress
02/04/201610:50:00Martin Shkreli Takes the Fifth Before Congress
02/03/201618:49:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/03/201618:30:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/03/201618:19:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/02/201620:12:00Correction to Companies Boosted Drug Prices To Fuel Preset Profits
02/02/201617:30:17Current Report Filing (8-k)
02/02/201616:20:00Valeant, Turing Boosted Drug Prices To Fuel Preset Profits
01/28/201616:12:26Statement of Changes in Beneficial Ownership (4)
01/25/201608:48:00Valeant's Pearson: 'On the Road to Recovery' -- 2nd Update
01/25/201608:00:00Valeant Announces FDA Acceptance of BLA Submission for Brodalumab...
01/25/201608:00:00Valeant Announces FDA Acceptance of BLA Submission for Brodalumab...
01/25/201607:00:00Valeant Provides Update On J. Michael Pearson
01/25/201607:00:00Valeant Provides Update On J. Michael Pearson

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad